Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74BELTSVILLE, Md., April 08, 2024 NextCure, Inc. , a clinical-stage biopharmaceutical company committed to.
- Samsung Biologics to develop and manufacture antibody for ADC candidate - Latest deal comes as Samsung Biologics is on track to complete construction of an ADC facility this year INCHEON, South Korea, Feb. 7, 2024
Samsung Biologics, South Korea's largest contract development and manufacturing organization, said Wednesday that it has signed a contract with LegoChem Biosciences to develop antibody-drug conjugate or simply ADC therapeutics, designed as targeted treatment for cancer. LegoChem Biosciences, founded in 2006, specializes in research and development capabilities in therapeutics, especially with a focus on AD.
DAEJEON, South Korea, December 26, 2023 LegoChem Biosciences Announces License Agreement for LCB84, a Trop2 directed ADC with Janssen Biotech, Inc., a Johnson & Johnson company.